retatrutide what is it clinical trials trial information Safety, Side Effects & Provider Use Retatrutide Dosing: Early Clinical Trial – Today, we shared new data

GLP-1 drugs, particularly semaglutide, have been shown to support weight loss, which might improve overall health and potentially reduce the burden of lupus symptoms

The idea is that tiny doses can give benefits with fewer side effects

This may be too dilute for typical protocols

Location: Plainsboro, New JerseyWarning Letter Date: September 9, 2025FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)Type of Warning: False & Misleading Claims/Misbranded DrugsSubject of Violation: An Oprah Special: Shame, Blame, and the Weight Loss Revolution, regarding Wegovy (semaglutide) injection, for subcutaneous use, Ozempic (semaglutide) injection, for subcutaneous use, and Victoza (liraglutide) injection, for subcutaneous use.FDA Warning: In the program, which aired on television in 2024 and until recently was available continuously on the ABC website and through various streaming services, Novo Nordisk promoted Wegovy, Ozempic, and Victoza in a manner that failed to present the serious risks of these drug products in a truthful and nonmisleading manner